<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343719</url>
  </required_header>
  <id_info>
    <org_study_id>1296.1</org_study_id>
    <secondary_id>2010-022465-96</secondary_id>
    <nct_id>NCT01343719</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 2 mg to 350 mg of BI 661051 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of a Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate safety, tolerability, and
      pharmacokinetics of treatment with BI 661051 rising single doses administered as oral
      drinking solution (powder in bottle) in healthy male subjects.

      The primary objective is to investigate the safety and tolerability of treatment with BI
      661051.

      The secondary objectives are (1) to evaluate the single dose pharmacokinetics of BI 661051,
      (2) to explore dose proportionality, (3) to explore the relative bioavailability when BI
      661051 is administered as tablet at two dose levels compared to oral drinking solution and
      (4) to assess the effect on the bioavailability when BI 661051 is administered as oral
      drinking solution after intake of a high fat meal.

      Pharmacodynamic parameters will not be determined within this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of findings of physical examination</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs (blood pressure (BP), pulse rate (PR), respiratory rate [RR])</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Orthostasis test parameters</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram (ECG) parameters (heart rate, PQ interval, QRS interval, uncorrected QT interval as well as Bazett- and Fridericia corrected QT interval)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory test parameters (haematology, clinical chemistry and urinalysis parameters)</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs) on the level of Medical Dictionary for Regulatory Affairs (MedDRA) Preferred Terms and MedDRA System Organ Class</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of findings detected by the pupillometry measurements</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability assessed by investigator</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable analyte plasma concentration)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 661051 low dose, low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 low dose, medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 low dose, high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 medium dose, low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 medium dose, medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 medium dose, high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 high dose, low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 high dose, medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for oral administration, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 661051 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>solution for oral administratrion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>medium dose solution for oral administration</description>
    <arm_group_label>BI 661051 medium dose, low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>medium dose solution for oral administration</description>
    <arm_group_label>BI 661051 medium dose, medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>medium dose solution for oral administration</description>
    <arm_group_label>BI 661051 medium dose, high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>low dose solution for oral administration</description>
    <arm_group_label>BI 661051 low dose, high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>low dose solution for oral administration</description>
    <arm_group_label>BI 661051 low dose, low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>low dose solution for oral administration</description>
    <arm_group_label>BI 661051 low dose, medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>high dose solution for oral administration</description>
    <arm_group_label>BI 661051 high dose, low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>high dose solution for oral administration</description>
    <arm_group_label>BI 661051 high dose, medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>low dose tablet</description>
    <arm_group_label>BI 661051 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution for administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 661051</intervention_name>
    <description>medium dose tablet</description>
    <arm_group_label>BI 661051 medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males based upon a complete medical history, including the physical
             examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead
             electrocardiogram (ECG), clinical laboratory tests. There is no finding deviating from
             normal and of clinical relevance. There is no evidence of a clinically relevant
             concomitant disease.

          2. Age =18 and age =50 years.

          3. BMI =18.5 and BMI =30 kg/m2 (Body Mass Index).

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation.

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance.

          2. Any evidence of a clinically relevant concomitant disease.

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders.

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders.

          5. History of relevant orthostatic hypotension, fainting spells or blackouts.

          6. Chronic or relevant acute infections.

          7. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients) as judged clinically relevant by the investigator.

          8. Intake of drugs with a long half-life (&gt;24 h) within at least 1 month or less than 10
             half-lives of the respective drug prior to administration.

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to randomisation.

         10. Participation in another trial with an investigational drug within 30 days prior to
             randomisation.

         11. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day).

         12. Inability to refrain from smoking on trial days as judged by the investigator.

         13. Alcohol abuse (more than 30 g/day).

         14. Drug abuse.

         15. Blood donation (more than 100 mL within 4 weeks prior to randomisation or during the
             trial).

         16. Excessive physical activities (within 1 week prior to randomisation or during the
             trial).

         17. Any laboratory value outside the reference range that is of clinical relevance.

         18. Inability to comply with dietary regimen of the study centre.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1296.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

